The results of the combination therapy with Rivoceranib (Apatinib) and Vinorelbine in patients with wild-type Non-Small Cell Lung Cancer (NSCLC) without standard therapy were published in a paper published in the JAMA Network Open of the Journal of the American Medical Association (JAMA).
1. Combination phase 2 sponsor-investigator trials of Rivoceranib and Vinorelbine
In Phase 2 clinical trials conducted by Central South University in China, the disease control rate (DCR) was 76.7%, the overall response rate (ORR) was 36.7%, the median Progression-Free Survival (mPFS) was 4.5 months, and the median Overall Survival (mOS) was 10 months and the major indicators had a meaningful effect.
The article mentioned that the combination treatment of Apatinib and Vinorelbine could be "a very promising treatment" because it was effective as a third-line treatment in NSCLC patients without the genetic mutation, and its toxicity was manageable.
Hengrui Medicine recently decided to promote phase 3 commercial trials, respectively, for the combination of Rivoceranib and Gefitinib and Rivoceranib and Camrelizumab for the purpose of first-line NSCLC treatment.
2. Lung cancer, the number one cause of death … with 80% of NSCLC
Lung cancer is the world's most common cancer and death.
The high rate of lung cancer mortality is due to the absence of early symptoms. Lung cancer is classified into NSCLC and Small Cell Lung Cancer (SCLC), and more than 80% of lung cancer patients are NSCLC.
Recently, if diagnosed with NSCLC, a genetic test will determine the treatment method by checking for the presence or absence of a gene mutation such as Epidermal Growth Factor Receptor (EGFR).
However, in the case of progressive NSCLC without gene mutation, normal cytotoxic chemotherapy is given, and there is no standard treatment for patients who have undergone secondary chemotherapy.
3. Meaning: Rivoceranib reaffirms as a basic drug for combination therapy, expecting royalty revenue to increase
The treatment of lung cancer is subdivided according to biomarkers such as EGFR, ALK, ROS1, and PD-L1, and the strength of Rivoceranib as a drug that can be used as the basis for combination therapy with various target drugs has been confirmed once again.
Last month, HLB signed an agreement from Advenchen Laboratories to acquire Rivoceranib's global rights, including China.
Recently, Hengrui Medicine recently applied for the marketing of Rivoceranib as a second-line liver cancer treatment in China, and various indications, such as phase 3 clinical trials of lung cancer, have been attempted to increase.